ACCESS PHARMACEUTICALS INC
10-Q, EX-27, 2000-08-14
PHARMACEUTICAL PREPARATIONS
Previous: ACCESS PHARMACEUTICALS INC, 10-Q, 2000-08-14
Next: BANCTEC INC, 10-Q, 2000-08-14



<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION FROM
THE CONSOLIDATED BALANCE SHEET AND THE CONSOLIDATED
STATEMENT OF INCOME FILED AS PART OF THE QUARTERLY REPORT ON
FORM 10-Q AND IS QUALIFIED IN ITS  ENTIRETY BY REFERENCE TO SUCH
QUARTERLY REPORT ON FORM 10-Q.
</LEGEND>

<MULTIPLIER>                  1,000

<S>                           <C>
<PERIOD-TYPE>                 6-MOS
<FISCAL-YEAR-END>             DEC-31-2000
<PERIOD-START>                JAN-01-2000
<PERIOD-END>                  JUN-30-2000
<CASH>                                999
<SECURITIES>                       12,519
<RECEIVABLES>                         140
<ALLOWANCES>                            0
<INVENTORY>                             0
<CURRENT-ASSETS>                   13,729
<PP&E>                              1,079
<DEPRECIATION>                        956
<TOTAL-ASSETS>                     17,195
<CURRENT-LIABILITIES>               1,476
<BONDS>                                 0
                   0
                             0
<COMMON>                              120
<OTHER-SE>                         15,599
<TOTAL-LIABILITY-AND-EQUITY>       17,195
<SALES>                                 0
<TOTAL-REVENUES>                        0
<CGS>                                   0
<TOTAL-COSTS>                       2,768
<OTHER-EXPENSES>                        0
<LOSS-PROVISION>                        0
<INTEREST-EXPENSE>                      3
<INCOME-PRETAX>                    (2,483)
<INCOME-TAX>                           43
<INCOME-CONTINUING>                (2,526)
<DISCONTINUED>                          0
<EXTRAORDINARY>                         0
<CHANGES>                               0
<NET-INCOME>                       (2,526)
<EPS-BASIC>                       (0.26)
<EPS-DILUTED>                       (0.26)




</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission